Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition strengthens Sobi’s leading haematology franchise by adding Vonjo (pacritinib), a novel oral kinase inhibitor that inhibits JAK2, IRAK1 and ACRV1, while sparing JAK1, for the treatment of adults with myelofibrosis. Vonjo obtained accelerated approval by the FDA.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition June 26, 2023
Details:
The acquisition will diversify Sobi's portfolio of leading hematology medicines through CTI's lead product, VONJO® (pacritinib), which is FDA-approved for the treatment of adult myelofibrosis patients with a platelet count below 50 x109/L.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition May 10, 2023
Details:
Vonjo (Pacritinib) is an oral kinase inhibitor with activity against wild type Janus Associated Kinase 2 (JAK2), mutant JAK2V617F form, IRAK1, ACVR1 (ALK2) and FMS-like tyrosine kinase 3 (FLT3).
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
On duplicate assays, Vonjo (pacritinib) was shown to be a more potent inhibitor of ACVR1 compared to momelotinib, with a half maximal inhibitory concentration (IC50) of 10.8 and 22.6 nM versus34.9 and 70.2 nM, respectively.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Vonjo (pacritinib) is an oral kinase inhibitor with activity against wild type JAK2, mutant JAK2V617F form and FMS-like tyrosine kinase 3 (FLT3), which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
Vonjo (Pacritinib) is an oral kinase inhibitor with activity against wild type JAK2, mutant JAK2V617F form and FMS-like tyrosine kinase 3, which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
FDA’s approval of VONJO (pacritinib) is based upon results of PERSIST-2 clinical trial indicate that 29% of myelofibrosis patients with baseline platelet levels of less than 50 x 109/L obtained spleen volume reductions of at least 35% during first six months of VONJO therapy.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Onco360
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2022
Details:
Vonjo (pacritinib), is an oral kinase inhibitor with activity against wild type JAK2, mutant JAK2V617F form and FLT3, contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
Pacritinib, a JAK 2/interleukin-1 receptor–associated kinase 1 (IRAK1) inhibitor that does not inhibit JAK1, is in development for use in patients with myelofibrosis who have thrombocytopenia.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: PAC203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021